Jiangsu wuzhong(SH:600200) Di Yi Cai Jing·2025-11-01 13:02Core Viewpoint - Jiangsu Wuzhong (600200.SH) is facing imminent delisting risks due to multiple violations, including significant financial losses and operational stagnation, as highlighted in recent announcements and financial reports [1][2][4]. Group 1: Delisting Risks - Jiangsu Wuzhong has issued a risk warning regarding potential delisting due to a face value breach, with a stock price currently at 0.99 yuan, down 89% year-to-date [1][2]. - The company is under investigation by the China Securities Regulatory Commission (CSRC) for major violations, including failure to disclose the actual controller and inflating financial figures from 2018 to 2023 [2][3]. - The company has been identified as having significant non-operational fund occupation by related parties, with amounts soaring from 127 million yuan in 2020 to 1.693 billion yuan in 2023, representing 96.09% of net assets [3]. Group 2: Financial Performance - Jiangsu Wuzhong reported a net loss of 87.468 million yuan for the first three quarters, with revenue dropping by 38.85% to 784 million yuan [1][4]. - The company's pharmaceutical business saw a 55.79% decline in revenue, while the medical beauty segment, previously seen as a growth area, is now under threat due to the termination of exclusive distribution rights for a key product [5][6]. - The third quarter alone showed a staggering revenue drop of 63.93% compared to the previous quarter, with a net loss of 43.0502 million yuan, marking a significant operational downturn [5][6].